Objectives:
The calcium sensitizer levosimendan is used in treatment of decompensated heart failure and may also exhibit antiinflammatory properties. We examined whether treatment with levosimendan is substantially beneficial in mice with cecal ligation and puncture-induced polymicrobial sepsis, and its arbitration mechanism was explored in the mouse macrophage cell line RAW264.7. Design: Laboratory and animal/cell research. Setting: University research laboratory. Subjects: BALB/c mice (8-10 wk old) and mouse macrophage cell line RAW264.7 cells. Interventions: Levosimendan (0.5 μg/kg/min) was administered to mice through an osmotic pump that was implanted into the peritoneal cavity immediately following surgery. In RAW264.7 cells, levosimendan was added to the culture medium 30 minutes before lipopolysaccharide. Measurements and Main Results: When levosimendan was continuously administered to cecal ligation and puncture-induced septic mice, a significant improvement of left ventricular function was found without any change in heart rate, and hypotension was significantly mitigated. Furthermore, levosimendan conferred substantial protection against sepsis-associated inflammation in mice, as indicated by reduced lung injury and decreased blood proinflammatory and chemotactic cytokine levels. These beneficial effects of levosimendan led to a significant improvement of survival in mice after cecal ligation and puncture. In endotoxin-stimulated RAW264.7 macrophages, treatment with levosimendan and pimobendan suppressed overproduction of proinflammatory and chemotactic cytokines. Levosimendan and pimobendan were without effect on activation of the nuclear factor-κB, mitogenactivated protein kinase, and Akt pathways. Instead, levosimendan and pimobendan prevented high mobility group box 1 release from the nucleus to the extracellular space in macrophages. This was associated with inhibition of the Rho kinase signaling pathway. The elevated serum high mobility group box 1 levels in cecal ligation and puncture-induced septic mice were also inhibited by continued administration of levosimendan and pimobendan. Conclusions: We define a novel mechanism for the anti-inflammatory action of levosimendan and suggest that the pharmacological profiles of levosimendan as both an inotrope and an anti-inflammatory agent could contribute to its clinical benefit in patients with sepsis with heart problems. (Crit Care Med 2015; 43:e508-e520) Key Words: hemodynamic dysfunction; high mobility group box 1; inflammation; levosimendan; macrophages; nuclear factor-κB; pimobendan; sepsis to one or more organ failure (3) . Septic shock is associated with hypotension requiring vasopressor support despite adequate fluid resuscitations in order to maintain vascular perfusion and results in disruption of the organ oxygen supply-demand balance, which also eventually contribute to the development of multiple organ failure (4) . Severe sepsis and septic shock are major causes of death in ICUs (5) . The number of patients with severe sepsis and septic shock continues to rise because of the gain in life expectancy and the increase in the number of immunocompromised patients, among other reasons (6) . The great mortality of severe sepsis and septic shock has intensified research seeking new strategies for the disease therapy.
Calcium-sensitizing agents are cardiac inotropes that have attracted growing interest over the nearly 30 years (7, 8) . They act as a direct activator of motor proteins such as myosin, an enhancer of force generated by a cross-bridge or an agent that augments Ca 2+ -troponin C by a cross-bridge (8, 9) . Levosimendan is the most widely studied calcium sensitizer to date and is clinically used against decompensated heart failure (9) (10) (11) . In a few limited trials and case series, some promising data indicate that levosimendan may specifically offset sepsis-associated cardiac dysfunction and thus improve hemodynamics (12, 13) . In this regard, several clinical trials of levosimendan in patients with septic shock have been run in a proactive way. Interestingly, available evidence suggests that levosimendan may also have anti-inflammatory properties (14, 15) . These composite actions of levosimendan raise the theoretical possibility that this agent may have value as a treatment of sepsis. Indeed, some benefits of levosimendan have been shown in different experimental animal models with septic shock (16) (17) (18) . However, the information on a set of the underlying mechanisms by which levosimendan may have a favorable impact on sepsis episodes is very limited.
Herein, we examined whether treatment with levosimendan is substantially beneficial in mice with cecal ligation and puncture (CLP)-induced polymicrobial sepsis. CLP-induced sepsis is an animal model that has high relevance to humans because it reproduces many hallmarks of sepsis that occur in patients (19) . Further studies were then undertaken using the mouse macrophage cell line RAW264.7 to gain insight into possible mechanism(s) involved in the ability of levosimendan to mitigate sepsis. In a series of in vitro experiments, pimobendan, which is approved for use in heart failure patients only in Japan (20) , was also used as another pyridazinone derivative calcium sensitizer.
MATERIALS AND METHODS

Animal Models of Sepsis and Drug Administration
All animal studies were conducted in accordance with the National Institute of Health Guidelines on the use of laboratory animal and with approval of the Care and Use Committee of the University of Toyama. The surgical procedure to generate CLP-induced sepsis was performed as previously described (21) (22) (23) . In brief, male BALB/c mice, 8-10 weeks old, were anesthetized with 3-4% sevoflurane, and a middle abdominal incision was made. The cecum was mobilized, ligated, and punctured twice with a 21-gauge needle, allowing exposure of faces, the bowel was repositioned, and the abdomen was closed with sterile suture. In the levosimendan-treated CLP group, microosmotic pumps (Alzet, model 1003D; Durect, Cupertino, CA) delivering levosimendan (0.5 μg/kg/min) were placed into the peritoneal cavity before the abdomen was closed. For point of reference, the human levosimendan IV dosage is 0.2 μg/kg/min (24) . Levosimendan was dissolved in a small amount of dimethyl sulfoxide and then diluted in a 5% (w/v) glucose solution. The placebo group received an equal volume of 5% glucose (100 μL) by the osmotic pump. Sham-operated control mice underwent the same procedure except for ligation and puncture of the cecum. We used a noninvasive computerized tail-cuff system for measuring blood pressure in mice (22, 25) .
Cell Culture RAW264.7 cells, a mouse macrophage cell line, were purchased from RIKEN BRC (Tsukuba, Japan) and maintained in 10-cm dishes with Dulbecco's modified Eagle's medium (DMEM) (Nacalai, Kyoto, Japan) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C in a humidified 5% Co 2 atmosphere. Cells in passages 8-12 were used in the experiments. When cells were treated with levosimendan or pimobendan, these agents were added 30 minutes before the challenge with lipopolysaccharide (LPS; Escherichia coli 055:B5; List Biological Laboratories, Campbell, CA).
Isolation of Peritoneal Macrophages
Five-to 8-week-old male BALB/c mice were injected intraperitoneally with 2 mL of 3% thioglycollate broth. Closed peritoneal lavage was performed using 10 mL ice-cold sterile phosphate buffer solution (PBS). Peritoneal exudate cells were collected and washed once with DMEM supplemented with 10% FBS. A couple of hours later, nonadherent contaminating cells were removed by washing with PBS. Peritoneal macrophages were cultured in DMEM overnight at 37°C in a humidified incubator containing 5% Co 2 before starting experiment.
Echocardiographic Measurements
Echocardiographic studies were carried out using an ultrasound animal-imaging system (Prospect; S-Sharp, Taipei, Taiwan) at a frequency of 40 MHz with a transducer (acoustic pressure, 0.59 MPa; MI = 0.09) with a diameter of 7 mm and a fixed focus at 12 mm. The left ventricular dimensions in diastole (LVDd) and in systole (LVDs) and percent fractional shortening (FS) were estimated using the M-mode measurements. Ejection fraction (EF) was calculated from derived volumes, which are computed based on the "Teicholz" equations.
Histologic Examination
For routine histology, inflation-fixed lungs were harvested, fixed, dehydrated, paraffin-embedded, and sliced into 4-μmthick sections (22, 23, 25) . After deparaffinization, slides were stained with hematoxylin and eosin using standard methods. A semiquantitative morphometric analysis of lung injury was performed by scoring from 0 to 4 (none, light, moderate, severe, very severe) for the following categories: neutrophil infiltration, pulmonary edema, and disorganization of lung parenchyma and hemorrhage (22, 23) . A total lung injury score was calculated by adding the individual scores in every animal and averaging the total values in each group. For apoptotic cell detection, terminal deoxynucleotidyl transferase dUTPmediated nick-end labeling (TUNEL) was performed using ApopTag Plus Peroxidase In Situ Apoptotic Detection Kit (Millipore, Billerica, MA) according to the manufacturer's instructions. Additional details are described elsewhere (23) .
Enzyme Immunoassay for Cytokines
Blood and culture medium levels of tumor necrosis factor (TNF), interleukin (IL)-1β, IL-6, and monocyte chemoattractant protein (MCP)-1 were measured by the use of commercially available enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. To measure the concentrations of high mobility group box (HMGB) 1 in serum or culture medium samples, HMGB1 Detection Kit (Chondrex, Redmond, WA) was used. The plate was read on a microplate reader (Nippon-InterMed, Tokyo, Japan). Assays were performed in duplicate.
RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated from cells or lung tissues with Sepazol-RNA I Super G (Nacalai). PrimeScript RT Master Mix (Takara Bio, Ohtsu, Japan) or ReverTra Ace quantitative real-time polymerase chain reaction (qPCR) Master Mix (Toyobo, Osaka, Japan) was used for the reverse transcription reaction, and real-time PCR analyses were performed using SYBR Premix Ex Taq II (Takara Bio) or THUNDERBARD SYBR qPCR Mix (Toyobo). The TNF primer sequences were 5′-GTTCTATG-GCCCAGACCCTCAC-3′ (sense) and 5′-GGCACCACTAGTTG-GTTGTCTTTG-3′ (antisense), the IL-1β primer sequences were 5′-TCCAGGATGAGGACATGAGCAC-3′ (sense) and 5′-GAAC-GTCACACACCAGCAGGTTA-3′ (antisense), the IL-6 primer sequences were 5′-CCACTTCACAAGTCGGAGGCTTA-3′ (sense) and 5′-GCAAGTGCATCATCGTTGTTCATAC-3′ (antisense), the MCP-1 primer sequences were 5′-GCATC-CACGTGTTGGCTCA-3′ (sense) and 5′-CTCCAGCCTACT-CATTGGGATCA-3′ (antisense), and the HMGB1 primer sequences were 5′-AGCCCTGTCCTGGTGGTATTTTCAA-3′ (sense) and 5′-GCTGTGCACCAACAAGAACCTGC-3′ (antisense). The internal standard used was the ubiquitously expressed housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which was determined with the primer pair (sense, 5′-TGTGTCCGTCGTGGATCTGA-3′; antisense, 5′-TTGCTGTTGAAGTCGCAGGAG-3′).
Western Blot Analysis
Blotting procedure, chemiluminescent detection, and densitometric analysis were performed as previously described by our laboratory (26) . Cells were harvested and lysed in 300 μL of radio-immunoprecipitation assay buffer (25 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, pH 7.4; Thermo, Rockford, IL) containing protease inhibitor cocktail on ice. The lysates were centrifuged at 18,000 × g for 10 minutes at 4°C, and the resulting supernatants were collected. The proteins in the supernatant were measured using BCA Protein Assay Kit (Thermo). When required, nuclear protein extracts from macrophages were prepared as described previously (27) . Total supernatants (10-30 μg of protein) were run on 12% or 14% polyacrylamide gel and electrotransferred onto polyvinylidene fluoride filter membrane. The membrane was blocked for 60 minutes at room temperature in Odyssey blocking buffer, followed by overnight incubation with primary antibody at 4°C. The membrane was washed four times with Tween-phosphate-buffered A, Kaplan-Meier survival curves. No deaths occurred in mice that underwent sham procedure (n = 8). Levosimendan was continuously given during the first 3 d after CLP. Twelve and 10 animals were used for untreated and levosimendan-treated CLP groups, respectively. All animals were given a subcutaneous injection of 600 μL of saline after the surgery. Mortality was observed over 5 d. B, Mean arterial blood pressure before and 6 and 12 hr after surgery. The data are presented as mean ± sem (n = 6 per group). *p < 0.05, **p < 0.01, ***p < 0.001 vs sham. # p < 0.05, ## p < 0.01 vs CLP alone. C, Heart rate changes 24 hr after surgery. The data are presented as mean ± sem (n = 4-8 per group). Note that there was no significant difference between each group. saline and incubated with IR-Dye-labeled secondary antibodies at room temperature for 120 minutes in the dark. Fluorescent of Infrared-Dye was analyzed by Odyssey CLx Infrared Imaging System (LI-COR Bioscience, Lincoln, NE).
The following antibodies, which are commercially available, were used: anti-human IκBα rabbit monoclonal antibody (1:1,000 dilution; #4812; Cell Signaling, Danvers, MA), anti-human nuclear factor (NF)-κB rabbit monoclonal antibody (1:1,000; #3034; Cell Signaling), anti-human extracellular signal-regulated protein kinase (ERK) 1/2 mouse monoclonal antibody (1:1,000; #4696; Cell Signaling), anti-human phospho-ERK1/2 (Thr-202/Tyr-204) rabbit monoclonal antibody (1:1,000; #4370; Cell Signaling), antihuman c-Jun N-terminal kinase (JNK) rabbit monoclonal antibody (1:1,000; #9258; Cell Signaling), anti-human phospho-stress-activated protein kinase/JNK (Thr-183/Tyr-185) mouse monoclonal antibody (1:1,000; #9255; Cell Signaling), anti-human p38 rabbit monoclonal antibody (1:1,000; #8690; Cell Signaling), anti-human phospho-p38 (Thr-183/Tyr-182) mouse monoclonal antibody (1:1,000; #9216; Cell Signaling), anti-human Akt rabbit polyclonal antibody (1:2,000; #4691; Cell Signaling), anti-human phospho-Akt (Ser-473) rabbit polyclonal antibody (1:1,000; #4060; Cell Signaling), anti-human HMGB1 rabbit polyclonal antibody (1:1,000; #3935; Cell Signaling), anti-human GAPDH chicken polyclonal antibody (1:2,000-4,000; #AB2302, Millipore), antihuman Ras homolog gene family, member A (RhoA) mouse monoclonal antibody (1:500; #ARH04, Cytoskeleton, Denver, CO), and anti-human lamin B goat polyclonal antibody (1:200; #sc-6216; Santa Cruz Biotechnology, Santa Cruz, CA).
NF-κB Luciferase Assay
RAW264.7 cells cultured in 96-well plates were cotransfected with 0.3 μg of pGL4.32-NF-κB-Luc plasmid DNA (encoding firefly luciferase; Promega, Madison, WI) and pGL4.74-hRluc/TK plasmid DNA (0.1 μg) (encoding Renilla luciferase; Promega) using the Lipofectamine LTX reagent (Life Technologies, Tokyo, Japan) in accordance with the manufacturer's protocol. After 24 hours, the cells were treated with LPS for 6 hours. Then, the cells were lysed and assayed for luciferase activity using the Dual-luciferase Reporter assay system (Promega) in a Lumat LB9507 luminometer (Berthold, Bad Wildbad, Germany).
RhoA Activation Assay
The levels of active guanine-5'-triphosphate (GTP)-bound RhoA were determined by pull-down GTP-bound RhoA with glutathione S-transferase (GST)-Rhotekin-Rho binding domain (RBD) coupled to colored glutathione-sepharose beads (Cytoskeleton). RAW264.7 cells were stimulated with 1 μg/mL LPS for 5 minutes and lysed with lysis buffer (Cytoskeleton). Lysates were centrifuged, and supernatants were incubated with beads coupled to GST-Rhotekin-RBD for 3 hours at 4°C. Beads were then washed with wash buffer (Cytoskeleton), and GTP-bound RhoA was eluted with the sample buffer. Amounts of active RhoA were determined by Western blot analysis.
Statistical Analysis
Numerical data are expressed as mean ± sem. Statistical assessment of the data was made by a repeated-measure one-way analysis of variance followed by Tukey multiple comparison test. The Gehan-Breslow-Wilcoxon test was used for comparing the survival curves. A difference in the changes in blood pressure between the groups was assessed by carrying out an F test followed by a t test.
The statistical significance was set at p value of less than 0.05.
RESULTS
Animal Survival, Hypotension, and Cardiac Performance After CLP
We initially examined whether levosimendan administration can confer a survival advantage to mice with CLP-induced polymicrobial sepsis. Approximately 70% of the animals subjected to CLP surgery died throughout the 5 days of observation. The animals, when continuously given levosimendan immediately after CLP, displayed a survival benefit. Thus, Kaplan-Meier survival analysis showed a statistically significant difference (p = 0.0342) between the two groups ( Fig. 1A) . A significant fall in mean arterial blood pressure was found in the animals subjected to CLP. Levosimendan administration significantly mitigated CLPinduced hypotension (Fig. 1B) .
There was no significant difference in heart rate between the three groups (Fig. 1C) .
As presented in the typical tracing images ( Fig. 2A) , echocardiography demonstrated that the LVDd was prone to decrease without changing the LVDs in CLP-induced septic mice, in comparison with sham-operated control mice (Fig. 2, B and C) . Consequently, septic mice had left ventricular (LV) dysfunction as shown by significant reductions in LV FS and EF (Fig. 2, D and E). Treatment of septic animals with levosimendan did not alter the fall in LV diastolic performance but caused a significant shortening in the LVDs, resulting in significantly improved cardiac function as measured by LV FS and EF.
Cytokine Levels and Lung Histopathology in CLP Mice
When blood levels of proinflammatory or chemotactic cytokines were measured using ELISA, the sham-operated control mice had very low levels of the cytokines examined here. After induction of sepsis by CLP, marked elevations in TNF, IL-1β, IL-6, and MCP-1 were observed. Treatment with levosimendan markedly inhibited their elevated blood levels (Fig. 3A) . We also examined changes in the levels of messenger RNA (mRNA) of these cytokines in lung tissues using real-time PCR. In lungs from septic mice, mRNA expression levels of TNF, IL-1β, IL-6, and MCP-1 were greatly increased. The increases in mRNA expression of these cytokines were obviously suppressed when levosimendan was given to septic mice (Fig. 3B) . Histopathologic analysis with hematoxylin and eosin staining of paraffin-embedded lung sections showed that CLP-induced septic mice displayed massive infiltration of inflammatory cells, marked congestion of pulmonary edema, thickening of the alveolar septum, and erythrocytes originating from ruptured capillary vessels in the lung tissues (Fig. 4A) .
In lungs from septic animals treated with levosimendan, these histopathologic changes were attenuated. Semiquantitative assessment using lung injury score revealed that the score was significantly lowered when septic mice received levosimendan administration (Fig. 4B) . The tissue sections were labeled with an in situ TUNEL assay to detect apoptotic cells in lungs. As depicted in Figure 4C , no TUNEL-positive cells were detectable in lung sections from sham-operated control animals. Induction of sepsis by CLP resulted in a marked appearance of TUNEL-positive cells. Morphologically, apoptotic cells were identified to endothelial cells of capillary vessels in the alveolar septa and to epithelial type II cells (25, 28) . In lungs from CLP mice given levosimendan, TUNELpositive cells were significantly reduced (Fig. 4D) , providing a protective effect of levosimendan treatment on sepsis-associated pulmonary cell apoptosis.
Inflammatory Signaling in LPS-Stimulated Macrophages
When LPS (1 μg/mL) was applied to mouse macrophage cell line RAW264.7 cells, gene expression levels of proinflammatory and chemotactic molecules were greatly up-regulated. Treatment with levosimendan (3-30 μM) or another pyridazinone derivative calcium sensitizer pimobendan (10-100 μM) suppressed the mRNA levels of TNF, IL-1β, IL-6, and MCP-1 in a concentration-dependent manner ( Fig. 5A) . When the amounts of proinflammatory and chemotactic cytokines in culture media were measured by ELISA, LPS challenge resulted in striking increases in protein levels of TNF, IL-1β, IL-6, and MCP-1 secreted by RAW264.7 cells, and their increased protein levels were greatly inhibited by levosimendan and pimobendan (Fig.  5B) . Additional experiments showed that levosimendan was significantly effective in inhibiting the release of these proinflammatory and chemotactic cytokines from LPS-stimulated RAW264.7 cells even when it was added at a concentration of 30 μM 30 minutes after LPS challenge (Fig. 5C) .
We also examined whether levosimendan can inhibit the LPS-induced overproduction of cytokines in primary peritoneal macrophages isolated from mice. Peritoneal macrophages stimulated with 1 μg/mL LPS showed a marked increase in the mRNA levels of TNF, IL-6, and MCP-1, which was significantly suppressed by treatment with 30 μM levosimendan (Fig. 6A) . In addition, a significant ability of levosimendan to inhibit the release of these proinflammatory and chemotactic cytokines from LPS-stimulated peritoneal macrophages was observed by ELISA techniques (Fig. 6B) . This indicates that the inhibition by levosimendan of LPS responses is not a cell line-specific effect. Figure 5 . Effects of levosimendan and pimobendan treatment on up-regulated expression of cytokines, tumor necrosis factor (TNF), interleukin (IL)-1β, IL-6, and monocyte chemoattractant protein (MCP)-1 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. Levosimendan (Levo) and pimobendan (Pimo) were given 30 min before LPS. A, Messenger RNA (mRNA) expression levels of TNF, IL-1β, IL-6, and MCP-1 (n = 6). Cells were exposed to 1 μg/mL LPS for 6 hr. Cytokine expression was normalized to glyceraldehyde-3-phosphate dehydrogenase. B, Cell culture media were collected 24 hr after application of 1 μg/mL LPS, and the concentrations of TNF, IL-1β, IL-6, and MCP-1 were measured by the enzyme-linked immunosorbent assay (ELISA) (n = 4). C, Levosimendan (30 μM) was added 30 min after LPS, and then TNF, IL-1β, IL-6, and MCP-1 levels in cell culture media at 24 hr after LPS were assessed by ELISA (n = 3). The data are presented as mean ± sem. ***p < 0.001 vs control. # p < 0.05, ## p < 0.01, ### p < 0.001 vs LPS alone.
The NF-κB signaling pathway plays a pivotal role in regulating many of key genes that mediate the inflammatory response (29, 30) . We examined whether the inhibitory effects of levosimendan and pimobendan on the production of proinflammatory and chemotactic cytokines are associated with their impacts on the NF-κB signaling pathway. Since the activity of NF-κB is primarily regulated by interaction with its inhibitory protein IκBα, degradation of IκBα after stimulation of RAW264.7 cells with LPS was monitored by Western blot. A peak reduction in IκBα was observed from 15 to 30 minutes after cells were exposed to LPS. Levosimendan and pimobendan did not substantially alter IκBα degradation when evaluated at 15 minutes following LPS challenge (Fig. 7A) . Liberation of NF-κB from degraded IκBα ultimately leads to NF-κB nuclear translocation. Stimulation of RAW264.7 cells with LPS resulted in the translocation of NF-κB p65 into the nucleus, but neither levosimendan nor pimobendan inhibited the nuclear translocation (Fig. 7B) . We also examined whether treatment with levosimendan or pimobendan can affect NF-κB transcriptional activity in LPS-stimulated RAW264.7 cells. In cells transfected with a reporter construct carrying a luciferase gene under the control of an NF-κB promoter containing five copies of an NF-κB response element, LPS stimulation for 6 hours markedly increased NF-κB transcriptional activity. Treatment with levosimendan or pimobendan tended to inhibit LPS-induced NF-κB activation, but their effects were not significant (Fig. 7C) .
The mitogen-activated protein kinase (MAPK) cascade is the key downstream pathway for LPS-stimulated signaling events (31) . Hence, we tested whether the suppression of proinflammatory and chemotactic cytokines is regulated through the MAPK pathways. The MAPK family involves three major subgroups, including ERK1/2, JNK, and p38. When activation of ERK1/2, JNK, and p38 was assessed by their phosphorylation levels, LPS strongly activated all three families of MAPKs in RAW264.7 cells. Neither levosimendan nor pimobendan prevented LPS-induced increase in levels of phosphorylated ERK1/2, JNK, and p38 ( Fig. 8) .
Akt is a serine/threonine kinase that is known to play a critical role in negatively regulating LPS-induced inflammation (32) . Akt was strikingly activated in LPS-stimulated RAW264.7 cells, as indicated by a great increase in Ser-473 phosphorylation of Akt. Levosimendan was without effect on LPS-induced Akt activation, whereas it was abrogated by treatment with pimobendan ( Fig. 8 ).
HMGB1 is a nuclear factor that enhances transcriptional activation but also serves as an extracellular cytokine known to be a critical mediator of innate immune responses (33, 34) . The HMGB1 mRNA levels were strongly down-regulated when RAW264.7 cells were exposed to LPS, which was partially but significantly reversed by treatment with levosimendan or pimobendan (Fig. 9A) . On the other hand, LPS challenge caused a marked release of HMGB1 proteins from RAW264.7 cells. Treatment with levosimendan resulted in a return of LPS-induced HMGB1 release from cells toward baseline (Fig. 9B) . In line with this finding, levosimendan and pimobendan prevented a reduction in HMGB1 protein levels in the nuclei of LPS-stimulated RAW264.7 cells (Fig. 9C) . Even when levosimendan was added 30 minutes after LPS challenge, the LPS-induced reduction in nuclear HMGB1 protein levels was partially reversed (Fig. 9D) . The Rho kinase inhibitor Y-27632 was also able to mitigate the LPS-induced reduction in nuclear . Cells were exposed to 1 μg/mL LPS for 6 hr. Cytokine expression was normalized to glyceraldehyde-3-phosphate dehydrogenase. B, Cell culture media were collected 24 hr after application of 1 μg/mL LPS, and the concentrations of TNF, IL-6, and MCP-1 were measured by the enzyme-linked immunosorbent assay (n = 3). The data are presented as mean ± sem. ***p < 0.001 vs control. ## p < 0.01, ### p < 0.001 vs LPS alone.
HMGB1 protein levels (Fig. 9E) . When we measured levels of GTP-bound active form of RhoA using pull-down assay with GST-Rhotekin, LPS strongly stimulated RhoA activity within 5 minutes and increased the level of active GTP-bound RhoA. This up-regulation of RhoA activity was negated by levosimendan ( Fig. 9F) . Finally, we examined serum HMGB1 levels in CLP-induced septic mice. Sepsis induction by CLP resulted in a marked elevation in serum HMGB1 in mice. Administration of levosimendan or pimobendan to CLP mice strongly suppressed the elevated levels of HMGB1 (Fig. 9G) .
DISCUSSION
Levosimendan belongs to a new class of cardiac inotropic agents, calcium sensitizers, and is currently approved in Europe and the United States for use in the management of acute decompensated heart failure, as levosimendan increases cardiac output without deleterious effects on myocardial oxygen consumption (35) . In this context, levosimendan may represent a beneficial effect on sepsis-associated cardiac dysfunction, although there is no definitive study supporting levosimendan as the best choice for septic patients with cardiac dysfunction (36) . In the experiments using transthoracic echocardiography, our rodent model of CLP-induced sepsis exhibited limited LV cardiac performance as demonstrated by low EF and FS. A significant improvement of LV function without change in heart rate was observed when levosimendan was continuously administered to septic mice. This beneficial effect of levosimendan on sepsis-induced cardiac dysfunction could be, at least in part, attributed to the increased cardiac output. Consequently, levosimendan administration significantly improved hypotension in septic mice.
The results of the present study also indicate that levosimendan can confer substantial protection against acute lung injury in CLP-induced septic mice. The proinflammatory cytokines, TNF and IL-6, have been implicated in the pathogenesis of inflammatory lung injury, particularly under conditions of severe lung infection and sepsis (37) . We found that when levosimendan was given to septic mice, elevated gene levels of proinflammatory and chemotactic cytokines in lungs were greatly inhibited, and histologic damage in lungs, including inflammatory infiltrate and parenchyma disorganization, was significantly mitigated. In addition, levosimendan administration reduced cell apoptosis in lungs as determined by TUNEL assay. Accumulating evidence suggests that cell apoptosis plays a key role in the development of organ failure and mortality associated with sepsis, and it may be potentially detrimental in septic lung injury (38, 39) . These findings are consistent with the results of other investigators, showing the beneficial effect of levosimendan on lung inflammation and apoptosis in CLP rats (18, 40) . Furthermore, we demonstrated the ability of levosimendan to inhibit the increase in circulating levels of proinflammatory and chemotactic cytokines after CLP-induced sepsis, implying that levosimendan administration can reduce systemic inflammation in septic mice.
The anti-inflammatory property of levosimendan was confirmed in in vitro experiments with RAW264.7 macrophages. Thus, levosimendan treatment strikingly inhibited proinflammatory and chemotactic cytokine productions in LPSstimulated RAW264.7 cells. The ability of levosimendan to suppress the up-regulated cytokine response to LPS was also found in primary mouse peritoneal macrophages. The NF-κB pathway plays a central part in the transcriptional regulation of expression of proinflammatory genes, including cytokines, chemokines, and adhesion molecules (41) . In a myriad of stimuli, commencing with LPS, IκBα is quickly phosphorylated, ubiquitinated, and degraded, releasing the NF-κB heterodimer, which then translocates from cytoplasm into nucleus to mediate the transcription of proinflammatory genes (42) . However, levosimendan did not substantially modify IκBα degradation, NF-κB p65 nuclear translocation, and NF-κB activity in LPS-stimulated RAW264.7 cells. This suggests that the inhibitory effect of levosimendan on overproduction of proinflammatory and chemotactic cytokines cannot be solely attributed to alterations in the NF-κB pathway. Similarly, recent report has shown that levosimendan and its stereoisomer dextrosimendan did not affect the DNA binding of NF-κB in response to LPS in J774 macrophages (43) . LPS stimulation leads to phosphorylation of various intracellular signaling pathways, including MAPKs and Akt, and activation of these signaling pathways contributes to the regulation of expression of genes encoding proinflammatory and chemotactic cytokines in monocytes/macrophages (44) (45) (46) . Some anti-inflammatory compounds that may be beneficial in septic animals have been reported to inhibit the MAPK pathway (47) (48) (49) . On the other hand, our recent work has shown that the protective effects of the agents defined as a specific phosphodiesterase type III inhibitor or a direct adenylate cyclase activator on acute lung injury in CLP-induced septic mice are attributable to activation of the Akt pathway (22) . However, levosimendan treatment was without effect on LPSinduced activation of MAPKs and Akt in macrophages, suggesting that the MAPK-and Akt-mediated signaling pathways are not a critical mechanism contributing to the ameliorating effect of levosimendan in septic mice.
In this study, we revealed that levosimendan is potential inhibitor of HMGB1 release. HMGB1 is constitutively expressed in quiescent macrophage/monocytes, stored in the nucleus, and actively secreted from stimulated immune cells (34) . In septic shock, HMGB1 could be secreted not only actively from activated immune cells, such as macrophages, but also passively from injured or dying cells. Levosimendan prevented LPS-induced nuclear deprivation and extracellular release of HMGB1 in RAW264.7 cells. Levosimendan appears to inhibit LPS-induced HMGB1 release irrespective of its transcriptional regulation. Indeed, HMGB1 mRNA levels were strongly decreased rather than increased in LPSstimulated RAW264.7 macrophages, and its decrease was partially reversed by levosimendan treatment. We also found that neither LPS nor levosimendan altered HMGB1 mRNA levels in primary peritoneal macrophages isolated from mice (T. Imaizumi et al, unpublished observations, 2015). Outside the cells, HMGB1 can activate proinflammatory cytokine release from immune cells, including TNF and IL-1β (50) . This may account for the possible mechanism(s) underlying the suppressive effect of levosimendan on overproduction of proinflammatory and chemotactic cytokines in in vivo and in vitro experiments. HMGB1 is considered as a critical regulator of sepsis severity. Blood HMGB1 concentrations are elevated in patients with sepsis (51) . Patients with sepsis who succumbed to infection had higher serum HMGB1 levels than those who survived (52) . We found that administration of levosimendan greatly suppressed the elevation in serum HMGB1 levels in CLP-induced septic mice. Our results thus indicate that HMGB1 may be one of the possible target molecules for levosimendan in sepsis treatment. The secretion of HMGB1 from activated immune cells is likely to be a highly regulated process involving multiple steps (53, 54) . A recent report has documented a key role of Rho kinase in HMGB1 secretion in sepsis (55) . Indeed, we found that the specific Rho kinase inhibitor Y-27632 eliminated the release of HMGB1 in LPS-stimulated RAW264.7 cells. Interestingly, levosimendan suppressed the LPS-stimulated activation of RhoA, suggesting that levosimendan may have inhibited HMGB1 release by suppressing the Rho kinase signaling pathway. However, further study will be required to figure out the intricate mechanisms underlying the regulation of HMGB1 release in understanding the sepsis pathophysiology. Pimobendan is another pyridazinone derivative calcium sensitizer and inhibited the up-regulation of proinflammatory and chemotactic cytokine expression in LPS-stimulated macrophages. Pimobendan behaved as the same way as levosimendan in terms of activation of the MAPK and NF-κB pathways, except that pimobendan, but not levosimendan, inhibited LPSinduced Akt activation in macrophages. However, whether the inhibition of Akt phosphorylation by pimobendan is responsible for its anti-inflammatory property appears questionable, as Akt is known to play a critical role in negatively regulating LPS-induced inflammation (32) . In analogy with levosimendan, pimobendan resulted in a great inhibition of LPS-induced facilitation of HMGB1 release from the nucleus in macrophages. We also found that continued administration of pimobendan strikingly decreased the elevations in serum HMGB1 levels in CLP mice. Our results represent evidence in favor of a class effect for the pyridazinone derivative calcium sensitizers with anti-inflammatory properties.
Levosimendan administration significantly improved the survival of mice after CLP. We showed that levosimendan mitigated cardiac dysfunction and hypotension, reduced lung injury, and inhibited the elevations in circulating levels of proinflammatory and chemotactic cytokines in CLP-induced septic mice. These salutary effects may contribute to a reduction in septic mortality. Fluid therapy is one of the cornerstones of management of patients with sepsis (56) . In this regard, our study design was fluid resuscitated after CLP. Thus, all animals used for survival study were given a subcutaneous injection of saline after the surgery because the impact of the levosimendan-induced increase in cardiac index on systemic hemodynamics might have been limited without fluid support.
One may argue that administration of levosimendan through an osmotic pump that was implanted into the peritoneal cavity following CLP does not accurately represent the clinical situation.
To determine the potential practical relevance thereof, the investigation of levosimendan administration after sepsis induction may well deserve further study. Intriguingly, levosimendan was capable of inhibiting HMGB1 release and proinflammatory cytokine overproduction in RAW264.7 cells even when it was added 30 minutes after LPS challenge, suggesting that postadministration of levosimendan may be effective in reducing endotoxic inflammation.
In conclusion, we demonstrate that levosimendan can mitigate hemodynamic failure, presumably arising from its Values are mean ± sem of four separate experiments. ***p < 0.001 vs control. ### p < 0.001 vs LPS alone. C, Nuclear proteins were extracted, and then, HMGB1 was detected by Western blot. Effects of 30 μM levosimendan and 100 μM pimobendan on HMGB1 nuclear contents in RAW264.7 cells were evaluated following 24-hr incubation with LPS. Levosimendan and pimobendan were added 30 min before LPS. Lamin B served as a nuclear marker. D, Cells were given 30 μM levosimendan 30 min after LPS application. LPS was challenged for 24 hr, and then nuclear HMGB1 proteins was detected by Western blot. E, Effect of 50 μM Y-27632 on decreased HMGB1 nuclear contents following 24-hr incubation with LPS was assessed by Western blot. The final concentration of 0.5% of dimethyl sulfoxide (DMSO) used as a solvent did not affect the nuclear HMGB1 content. F, Ras homolog gene family, member A (RhoA) activity measurements. Cells were treated with or without 30 μM levosimendan. Cells were then further incubated with LPS for 5 min. Active guanine-5'-triphosphate (GTP)-bound RhoA was assayed by pull-down with GST-Rhotekin-Rho binding domain (RBD) coupled to colored glutathionesepharose beads. G, Serum HMGB1 levels in 24-hr cecal ligation and puncture (CLP) mice. Levosimendan (0.5 μg/kg/min) or pimobendan (7.5 μg/kg/min) was continuously given through an osmotic pump that was implanted into the peritoneal cavity immediately following CLP. The data are presented as mean ± sem (n = 3-4 per group). *p < 0.05 vs control.
Critical Care Medicine www.ccmjournal.org e519 cardiac inotropy, but also confer substantial protection against cytokine-mediated inflammation in mice with CLP-induced sepsis. The critical step for levosimendan anti-inflammatory action can be partly explained by the current evidence that levosimendan is an effective inhibitor of HMGB1 release and its proinflammatory function. Thus, levosimendan with such anti-inflammatory profiles may potentially offer a therapeutic option as an inotrope in treatment of decompensated heart failure in patients with severe sepsis and septic shock.
